ImmunoGen, Inc. is a clinical-stage biotechnology firm that develops targeted cancer therapeutics using its antibody-drug conjugate technology. The company has market cap of $278.61 million. The Firm is engaged in the discovery of monoclonal antibody anticancer therapeutics. It currently has negative earnings. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
The broker have set target price per share of GBX 660.00 on Homeserve PLC (LON:HSV) shares. This is 5.98% from the current stock price. In an analyst note revealed to clients and investors on 6 April, Liberum Capital maintained their “Buy” rating on shares of HSV.
Among 8 analysts covering Homeserve PLC (LON:HSV), 5 have Buy rating, 1 Sell and 2 Hold. Therefore 63% are positive. Homeserve PLC has GBX 695 highest and GBX 257 lowest target. GBX 609.25’s average target is -1.14% below currents GBX 616.29 stock price. Homeserve PLC had 42 analyst reports since August 6, 2015 according to SRatingsIntel. Liberum Capital maintained Homeserve plc (LON:HSV) on Thursday, August 6 with “Buy” rating. The rating was maintained by Jefferies with “Hold” on Wednesday, November 23. The rating was maintained by Liberum Capital with “Buy” on Wednesday, May 4. The rating was maintained by Liberum Capital with “Buy” on Tuesday, May 24. Liberum Capital maintained the stock with “Buy” rating in Wednesday, February 17 report. The firm earned “Neutral” rating on Monday, February 6 by JP Morgan. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, September 25. Citigroup maintained the shares of HSV in report on Tuesday, September 29 with “Buy” rating. JP Morgan maintained it with “Neutral” rating and GBX 415 target in Friday, April 1 report. As per Monday, March 13, the company rating was downgraded by Jefferies.
About 614,346 shares traded or 60.49% up from the average. Homeserve plc (LON:HSV) has declined 2.41% since September 7, 2016 and is downtrending. It has underperformed by 10.54% the S&P500.
HomeServe plc is a United Kingdom-based company, which is engaged in providing home emergency, repair and heating installation services. The company has market cap of 1.91 billion GBP. The Company’s divisions include UK, USA, France, Spain and New Markets. It has a 31.03 P/E ratio. The Firm creates a range of water, heating and electrical related home assistance products.
The stock decreased 9.16% or $0.34 during the last trading session, reaching $3.37. About shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has risen 17.01% since August 30, 2016 and is uptrending. It has outperformed by 8.89% the S&P500.
Orbimed Advisors Llc holds 0.16% of its portfolio in ImmunoGen, Inc. for 6.10 million shares. Twin Focus Capital Partners Llc owns 113,216 shares or 0.15% of their US portfolio. Moreover, Pinnacle Associates Ltd has 0.07% invested in the company for 1.62 million shares. The New York-based Baker Bros. Advisors Lp has invested 0.06% in the stock. Lumbard & Kellner Llc, a New Hampshire-based fund reported 40,731 shares.
Analysts await ImmunoGen, Inc. (NASDAQ:IMGN) to report earnings on May, 5. They expect $-0.36 earnings per share, up 2.70% or $0.01 from last year’s $-0.37 per share. After $-0.39 actual earnings per share reported by ImmunoGen, Inc. for the previous quarter, Wall Street now forecasts -7.69% EPS growth.
Since January 1, 0001, it had 6 insider purchases, and 0 selling transactions for $150,068 activity.
Ratings analysis reveals 33% of Immunogen’s analysts are positive. Out of 6 Wall Street analysts rating Immunogen, 2 give it “Buy”, 1 “Sell” rating, while 3 recommend “Hold”. The lowest target is $7 while the high is $24. The stock’s average target of $13.80 is 309.50% above today’s ($3.37) share price. IMGN was included in 8 notes of analysts from August 3, 2015. The stock has “Buy” rating by Jefferies on Wednesday, November 25. The stock has “Outperform” rating by RBC Capital Markets on Monday, July 27. Cantor Fitzgerald downgraded ImmunoGen, Inc. (NASDAQ:IMGN) on Monday, August 3 to “Neutral” rating. RBC Capital Markets downgraded the shares of IMGN in report on Friday, April 29 to “Sector Perform” rating. On Monday, May 2 the stock rating was maintained by Leerink Swann with “Market Perform”. Leerink Swann maintained ImmunoGen, Inc. (NASDAQ:IMGN) rating on Wednesday, October 28. Leerink Swann has “Market Perform” rating and $14 target. The company was downgraded on Monday, September 21 by Morgan Stanley. The stock of ImmunoGen, Inc. (NASDAQ:IMGN) has “Outperform” rating given on Wednesday, July 29 by Oppenheimer.
